Despite growing evidence of the potential of CDK4/6 inhibitors to slow bone progression in breast cancer patients with bone metastases, the effects of these drugs on the bone microenvironment are not fully understood, and the clinical implications of these effects remain unclear. This evidence concerns the gene CDK4 and breast cancer.